|Therapeutic Candidate||Target||Trial Link||Trial Description|
Study of DKN-01 in Combination with Paclitaxel in Patients with Refractory/recurrent Esophageal or Gastro-esophageal Junction Cancer
Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder
|TRX518||GITR||NCT01239134||Study of TRX518 in Stage III or IV Malignant Melanoma or Other Solid Tumors|
|TRX518||GITR||NCT02628574||Dose Escalation Study of TRX518 in Adults With Advanced Solid Tumors|
Translating Cancer Research to Patients
Leap Therapeutics’ current clinical program includes product candidates targeting esophageal cancer, a form of bile duct cancer known as cholangiocarcinoma, and other solid tumor malignancies. Details on our clinical trials are summarized below.